NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.
Exonhit's Genome-Wide SpliceArray platform will be used to identify progression and other biomarkers "that could segregate healthy elderly controls, patients with mild cognitive impairment … and patients with AD," the Paris-based company said.
Pfizer will provide samples from each of the three patient groups for the study.
Financial and other terms of the collaboration were not disclosed.
Exonhit's GWSA platform is a microarray-based technology that uses specific probe configuration to monitor RNA splice variants. It monitors known and predicted alternative RNA splicing events in about 21,000 human genes, Exonhit said.